RESUMO
We report the case of a 13-year-old female who presented with punctate, erythematous macules coalescing into patches on the upper extremities and left thigh. A skin biopsy demonstrated dilated capillary-sized blood vessels in the papillary dermis consistent with a diagnosis of cutaneous collagenous vasculopathy (CCV). To our knowledge, this is the youngest patient to present with CCV and will represent the third pediatric case in the literature.
Assuntos
Dermatopatias Vasculares , Telangiectasia , Feminino , Humanos , Criança , Adolescente , Dermatopatias Vasculares/diagnóstico , Dermatopatias Vasculares/patologia , Telangiectasia/diagnóstico , Pele/patologia , Veias , BiópsiaRESUMO
Disorders involving follicular occlusion, such as hidradenitis suppurativa, folliculitis, acneiform eruptions, and pilonidal cysts, have shown an increased prevalence in the Down syndrome (DS) population, but there are limited published data examining this association. We conducted a retrospective chart review of 243 DS patients presenting to a pediatric dermatology clinic to further examine the prevalence of disorders of follicular occlusion in DS patients. Our study showed high rates of disorders of follicular occlusion in DS patients, with prevalent disorders including folliculitis (21.0%), keratosis pilaris (17.3%), acne vulgaris (11.1%), hidradenitis suppurativa (7.0%), and furunculosis (4.5%), and overall prevalence of 44.9%. These findings add to a limited but growing body of evidence that documents an increased rate of disorders of follicular occlusion in pediatric DS patients.
Assuntos
Cistos/epidemiologia , Síndrome de Down/epidemiologia , Dermatopatias/epidemiologia , Adolescente , Criança , Pré-Escolar , Cistos/etiologia , Síndrome de Down/complicações , Folículo Piloso , Humanos , Lactente , Recém-Nascido , Masculino , Prevalência , Estudos Retrospectivos , Dermatopatias/etiologia , Texas/epidemiologiaAssuntos
Exantema , Anormalidades da Pele , Neoplasias das Glândulas Sudoríparas , Siringoma , Feminino , HumanosRESUMO
The association between immunosuppressive therapy for dermatologic conditions and the subsequent reactivation of hepatitis B is of major medical concern. It remains a point of interest across multiple disciplines, including hepatology, dermatology, rheumatology, and infectious disease. Accordingly, we present an evidence-based practice algorithm on how best to approach a patient with presumptively cleared hepatitis B infection when anticipating the initiation of immunosuppressive therapy. This guide delineates the risk of reactivation by taking into account the immunosuppressive agent of choice and presents recommendations for antiviral prophylaxis and laboratory monitoring. Booster vaccination as a potential to decrease the risk of hepatitis B reactivation is likewise discussed. (SKINmed. 2021;19:-0).